SAN DIEGO, Sept. 7, 2010 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the
Morgan Stanley Global Healthcare Conference on Monday, September 13, 2010 at 10:55 a.m. ET /
7:55 a.m. PT in New York, and at
the Baird Global Healthcare Conference on Tuesday, September 14, 2010 at 11:30 a.m. ET /
8:30 a.m. PT in New York.
Daniel M. Bradbury, president and
chief executive officer of Amylin Pharmaceuticals, will provide a
corporate overview at the Morgan Stanley conference. Alex Casdin, vice president, finance of Amylin,
will provide a corporate overview at the Baird conference.
The presentations will be webcast live through the "Investors"
section of Amylin's corporate Web site at www.amylin.com, and the
recordings will be made available on the Web site following the
events. To access the live webcasts, please log on to Amylin's Web
site approximately fifteen minutes prior to the presentations to
register and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated
to improving lives of patients through the discovery, development
and commercialization of innovative medicines. Amylin has developed
and gained approval for two first-in-class medicines for diabetes,
SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide)
injection. Amylin's research and development activities leverage
the Company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is headquartered in
San Diego, California. Further
information about Amylin Pharmaceuticals is available at
www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.